Benralizumab for eosinophilic asthma: results from the SHAMAL study

Patients with severe eosinophilic asthma have high levels of eosinophils, which are associated with repeated asthma symptoms or attacks despite using multiple medications. Inhaled corticosteroids (ICS)/long-acting beta-2 agonists (LABA) reduce asthma symptoms, but long-term use of high-dose ICS can lead to numerous steroid-related side effects. Asthma management guidelines recommend reducing ICS doses in patients who respond to biologic medications, but there is no evidence to support how safe this is. Benralizumab is a biologic injection that reduces eosinophil levels in the blood, thereby reducing inflammation and asthma flare-ups. This video presents results from the SHAMAL study, which investigated whether patients whose severe eosinophilic asthma was controlled with benralizumab could safely and effectively lower their ICS/LABA dose. Participants were assigned to one of two treatment groups; one group maintained their high-dose ICS/LABA, while the other group gradually reduced their dose of ICS/LABA. The study assessed the number of participants who reduced their dose of ICS/LABA, as well as other measures including asthma flare-ups, breathing test performance, and adverse events. Results showed that most patients with severe eosinophilic asthma treated with benralizumab can reduce their ICS/LABA dose while maintaining asthma control, with support from healthcare providers.Watch the Video Article here: https://doi.org/10.1080/26315904.2026.2648866